Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Low Prevalence of Hepatitis G Virus Antibodies in Glomerular Diseases

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A possible agent for human non-A–E hepatitis has been identified and named hepatitis G virus (HGV). HGV is also a flavivirus, and the clinical characteristics and risk factors of HGV infection may be similar to those of hepatitis C virus infection. Hepatitis C virus infection may manifest as a primary glomerulonephritis. The aim of this study is to evaluate the prevalence of serum HGV RNA in 98 adult patients with biopsy-proven glomerular diseases. We found that only 3 patients (3%) out of 98 with primary glomerulonephritis had HGV RNA. One of 59 (1.7%) healthy controls was serum HGV RNA positive (p > 0.05). The prevalence of serum HGV RNA was low in the patients with primary glomerulonephritis.

          Related collections

          Most cited references 2

          • Record: found
          • Abstract: found
          • Article: not found

          Infection with hepatitis GB virus C in patients on maintenance hemodialysis.

          A recently discovered non-A-E hepatitis virus has been designated hepatitis GB virus C (HGBV-C), but little is known about its mode of transmission and its clinical manifestations. We studied 519 patients on maintenance hemodialysis to determine whether they were infected with HGBV-C. HGBV-C RNA was identified in serum by a reverse-transcription-polymerase-chain-reaction assay with nested primers deduced from a non-structural region. A nucleotide sequence of 100 bp in the nonstructural region was determined on HGBV-C clones. HGBV-C RNA was detected on 3.1 percent of the patients on hemodialysis (16 of 519), as compared with 0.9 percent of healthy blood donors (4 of 448, P<0.03). None of the 16 patients had evidence of active liver disease, although 7 were also infected with hepatitis C virus. Eight patients with HGBV-C infection were followed for 7 to 16 years. In two patients the virus was present at the start of hemodialysis. One had a history of transfusion, and HGBV-C persisted over a period of 16 years; the other became free of HGBV-C after 10 years. In five patients, HGBV-C RNA was first detected 3 to 20 weeks after blood transfusion and persisted for up to 13 years. One patient with no history of transfusion was infected with an HGBV-C variant with the same sequence as in two of the patients with post-transfusion HGBV-C infections. Patients on maintenance hemodialysis are at increased risk for HGBV-C infection. This virus produces persistent infections, which may be transmitted by transfusions but may also be transmitted by other means.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Hepatitis GB Virus C in Patients on Hemodialysis

              Bookmark

              Author and article information

              Journal
              NEF
              Nephron
              10.1159/issn.1660-8151
              Nephron
              S. Karger AG
              1660-8151
              2235-3186
              1998
              August 1998
              29 July 1998
              : 79
              : 4
              : 472-473
              Affiliations
              Departments of a Nephrology, b Microbiology, and c Biochemistry, Ondokuzmayιs University, Samsun, Turkey
              Article
              45095 Nephron 1998;79:472–473
              10.1159/000045095
              9689165
              © 1998 S. Karger AG, Basel

              Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

              Page count
              Pages: 2
              Product
              Self URI (application/pdf): https://www.karger.com/Article/Pdf/45095
              Categories
              Short Communication

              Cardiovascular Medicine, Nephrology

              Glomerular diseases, Hepatitis G virus

              Comments

              Comment on this article